PBS293 / Promatix Biosciences - LARVOL DELTA

Promatix Biosciences Presents Positive Preclinical Data with First-in-Class PBS293 EGFR×EphA2 Cis-Bispecific ADC Demonstrating Enhanced Tumour Selectivity (GlobeNewswire) - "Data presented at 16th World ADC London Summit with lead programme in colorectal cancer highlight the promise of Promatix’s proteomics-based platform to optimise cis-bispecific antibody-drug conjugate (ADC) discovery and design....Promatix lead ADC PBS293-MMAE was 50x more potent than cetuximab-MMAE in the KRAS mutant colorectal cell line HCT116 and showed superior tumour growth inhibition in xenograft studies using the same cell line."

Preclinical • Colorectal Cancer